Skip to search formSkip to main contentSkip to account menu

OPC 13013

Known as: OPC-13013 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

cilostazol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1986
1986
Effect of cilostazol on experimental cerebral infarction in rabbits.
The effects of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3, 4-dihydro-2(1H)-quinolinone (cilostazol, OPC-13013… 
1986
1986
Clinical evaluation of OPC-13013, a new platelet aggregation inhibitor, or chronic arterial occlusive diseases : dose finding study by double-blind method
1986
1986
血小板凝集抑制剤 OPC-13013 のヒト脳循環代謝に及ぼす影響
1985
1985
Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors, IV. Synthesis and biological activity of the metabolites of 6-[4-(1-cyclohexyl-1H-5-tetrazolyl)butoxy]-2-oxo-1,2,3,4…
The metabolites of 6-[4-(1-cyclohexyl-1H-5-tetrazolyl) butoxy]-2-oxo-1, 2, 3, 4-tetrahydroquinoline (OPC-13013) (1), which has a… 
1985
1985
Antiaggregatory effect of oral cilostazol and recovery of platelet aggregability in patients with cerebrovascular disease.
A new antithrombotic drug, cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)- qui nolinone, OPC-13013… 
1985
1985
Effect of cilostazol, a new antithrombotic drug, on an experimental model of peripheral circulation insufficiency.
Acute arterial obstruction in hind limb was experimentally induced by intra-arterial injection of sodium laurate saline solution… 
1985
1985
The localization of a new antithrombotic agent, cilostazol, in CHO-K1 cells as demonstrated by autoradiography.
Cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)- qui nolinone, OPC-13013), a new antithrombotic agent… 
1984
1984
Effects of 6-〔4-(1-cyclohexy-5-tetrazolyl)-butoxy〕-1,2,3,4-tetrahydro-2-oxo-quinoline (OPC-13013) on platelet functions